In 2015, Bluestone led a small clinical trial to isolate and grow Tregs from diabetes patients and then reinfuse the cells ...
While most of what the FDA laid out in a recent draft guidance on the assessment of overall survival in oncology clinical ...
It is financial reporting season, and a few major medtech companies posted third-quarter sales growth. | It is financial ...
Neuphoria Therapeutics’ lead candidate has failed to improve social anxiety symptoms in a late-stage trial, prompting the ...
Unless a white knight emerges to rescue the business, Galapagos will start a wind-down process that will affect around 365 ...
A retinal implant developed by Science Corp. has for the first time restored some functional vision to patients with a severe ...
The U.S. private equity market is showing signs of recovery, with strong deal activity and lower interest rates driving ...
Meanwhile, AstraZeneca’s Enhertu partner Daiichi arrived at ESMO armed with its own ADC data for the cadherin-6-targetting ...
Walmart will become the first U.S. retailer to sell Abbott’s continuous glucose monitoring device as the medtech giant looks to broaden its sales potential for its growing business unit. | Walmart ...
After rejecting Replimune’s melanoma drug RP1 this summer, the FDA has accepted the biotech’s resubmission of an approval ...
BioNTech won’t proceed with further development of its BNT111 cancer vaccine candidate in a specific late-stage refractory ...
Under the terms of a deal that rescued the once-rejected tebipenem HBr, GSK will file for approval of the oral antibiotic. Back in 2022, after the FDA requested another phase 3 trial and denied ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback